PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
9.68M
Worse than FBIO's estimated revenue of 73.02M.
-1.93M
Better than FBIO's estimated ebitda of -73.02M.
-1.38
Better than FBIO's estimated eps of -1.72.
-41.62M
Worse than FBIO's estimated net income of -35.75M.
-1.93M
Better than FBIO's estimated ebit of -73.02M.
358.54M
Worse than FBIO's estimated sg&a expense of 97.87M.
Analyze DCF forecasts for the company and compare them with competitors.
81.00K
Worse than FBIO's revenue of 84.51M.
-92.14%
Worse than FBIO's revenue growth rate of 11.58%.
-51.13M
Better than FBIO's ebitda of -133.64M.
-63123.46%
Worse than FBIO's ebitda margin of -158.13%.
-51.92M
Better than FBIO's ebit of -141.72M.
-64098.77%
Worse than FBIO's ebit margin of -167.69%.
790.00K
Better than FBIO's depreciation of 8.07M.
76.68M
Worse than FBIO's total cash of 80.93M.
94662.96%
Better than FBIO's cash as percentage of revenue of 95.76%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
7.95M
Better than FBIO's accounts payable of 34.81M.
9818.52%
Worse than FBIO's payables as percentage of revenue of 41.19%.
-153.00K
Better than FBIO's capital expenditure of -63.00K.
-188.89%
Better than FBIO's capex as percentage of revenue of -0.07%.
4.99%
Better than FBIO's weighted average cost of capital (wacc) of 8.27%.
5.02%
Better than FBIO's cost of equity of 12.83%.
4.08%
Better than FBIO's cost of debt of 15.26%.
-0.23
Better than FBIO's beta of 1.86.
30.07M
Worse than FBIO's diluted shares outstanding of 20.78M.
1.57M
Better than FBIO's total debt of 75.96M.
49.31M
Better than FBIO's total equity of 37.62M.
50.89M
Worse than FBIO's total capital of 113.58M.
3.09%
Better than FBIO's debt weighting of 66.88%.
96.91%
Better than FBIO's equity weighting of 33.12%.
-51.92M
Better than FBIO's ebiat of -55.93M.
-53.46M
Worse than FBIO's unlevered free cash flow of -53.45M.
2.00%
Equal to FBIO's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than FBIO's net debt of 18.70M.
71.33M
Better than FBIO's equity value of -742.45M.
2.37
Better than FBIO's equity value per share of -35.72.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.